BLEOMYCIN ADMINISTRATION RESULTS in increased reactive oxygen species (ROS) that can cause severe organ injury. Pulmonary injury in response to systemic bleomycin treatment is thought to be prominent because of diminished bleomycin inactivating enzymes in the lungs (29) . Bleomycin complexes with iron to generate ROS that damage proteins, lipids, and DNA (4, 18) . Although intracellular ROS are prominent after bleomycin administration (17) , extracellular ROS may also be important mediators of lung injury because bleomycin binds to plasma membranes (33) and is found in the extracellular space several hours after administration (9) .
There are several lines of evidence that implicate superoxide as one of the ROS that mediate lung injury. First, bleomycin intercalates with DNA to cause strand breakage via oxygen free radicals (18) . Second, cytosolic superoxide dismutase (SOD) can attenuate DNA breakage in vitro (14) . Third, bleomycin induces cytosolic SOD activity in the lung (11, 15) and specifically in type II alveolar cells (19) . However, additional lines of evidence implicate extracellular superoxide as another source of oxidant stress created by bleomycin. First, plasma levels are detectable several days after bleomycin administration (9) . Second, bleomycin does not readily cross the plasma membrane but binds to cell surfaces before being endocytosed (8, 33) . Third, bleomycin increases lung leukocytes that subsequently release high levels of extracellular superoxide (39) . Fourth, parenterally administered cytosolic SOD, which essentially functions as an extracellular superoxide dismutase (EC-SOD), inhibits bleomycin-induced pulmonary fibrosis (20, 31, 43) . Thus many in vitro studies directly implicate intracellular superoxide as mediating bleomycin-induced injury, but the evidence implicating extracellular superoxide is only indirect.
SOD enzymes are the primary defense against excess superoxide. Mammals have three SOD enzymes: in the cytosol, SOD1 (28) ; in mitochondria, SOD2 (42) ; and in the extracellular space, SOD3 (24) . Of the three known mammalian SODs, only the intracellular SODs have been studied in bleomycin lung injury; however, EC-SOD's unique extracellular location and its abundance in the lung suggest that it may play a major role in attenuating free radial injury in the lung after bleomycin administration.
In this present study, intratracheal bleomycin was used to test the hypothesis that bleomycin could induce lung EC-SOD, and immunohistochemistry was used to characterize the histological distribution of EC-SOD after bleomycin-induced lung injury. Furthermore, mice overexpressing human EC-SOD in the lung were used to test the hypothesis that high levels of EC-SOD could protect the lung from bleomycin-induced fibrosis.
EXPERIMENTAL PROCEDURES

Reagents. Enhanced chemiluminescence (ECL) ϩPlus
Western blotting detection reagents were from Amersham Pharmacia Biotech (Piscataway, NJ). The protease inhibitors 3,4-dichloroisocoumarin, 1,10-phenanthroline (Boehringer Mannheim), and E-64 (ICN, Costa Mesa, CA) were kept in stock ethanol solution at Ϫ20°C. The Vectastain ABC Elite kit and biotinylated anti-rabbit IgG were from Vector Laboratories (Burlingame, CA). Bleomycin sulfate was from Mead Johnson Oncology Products. At a dose of 0.2 U/20 g mouse, this preparation was found to induce fibrosis without causing a significant mortality. All other reagents were from Sigma.
Bleomycin administration. C57/Bl6 mice overexpressing human EC-SOD using a surfactant protein C (SPC) promoter have been previously described (12) . Bleomycin administration was performed on 4 separate days using multiple animals from each group. Transgene-positive (n ϭ 58) or -negative (n ϭ 56) littermates (average age 62 days) were anesthetized with halothane and then given intratracheal bleomycin sulfate 0.2 U/20 g. Control mice, either transgene negative (n ϭ 14) or positive (n ϭ 13), were given vehicle. Mice were weighed daily and given liberal access to food and water and then killed at the end of a fortnight. Lung volumes were calculated by displacement of water after being fixed for 30 min with 4% paraformaldehyde at 20 cmH 2O pressure.
Histochemistry and immunohistochemistry. Half of the mice had their lungs inflated for 30 min with 4% paraformaldehyde at 20 cmH 2O pressure and embedded in paraffin. Multiple 4-m sections were made of each sample. They were then treated twice in Hemo-D for 7 min, twice in 100% ethanol for 5 min, twice in 90% ethanol for 5 min, and then placed in distilled H 2O for 5 min. One section of each sample was used for hematoxylin and eosin (H&E), Masson's trichrome, or immunohistochemical staining. For immunohistochemistry, the samples were blocked overnight at 4°C in blocking buffer (25 mM Tris pH 7.5, 500 mM NaCl, 1% Tween 20, 10% fish gelatin, and 0.05% NaN3). The samples were then incubated with 20% glycerol in H2O for 30 min and washed with blocking buffer. The sections were incubated with 1/100 affinity purified rabbit polyclonal anti-EC-SOD IgG or 1/2,000 rabbit IgG in blocking buffer for 3 h at room temperature. The sections were washed in high-salt buffer (25 mM Tris pH 7.5, 500 mM NaCl, and 1% Tween 20) three times for 5 min. A biotinylated anti-rabbit IgG, at 1/500 in blocking buffer, was placed on the sections for 30 min at room temperature. The sections were washed one time with highsalt buffer then treated for 3-5 min in 3% H2O2 in water. The samples were then washed two times for 5 min in high-salt buffer without detergent. Vectastain ABC Elite and diaminobenzidine (Vector Laboratories) kit were used as described in the kit instructions. The sections were then stained for 3 min with 1% methyl green and washed with distilled H2O. The sections were then dehydrated twice in 90% ethanol for 5 min, twice in 100% ethanol for 7 min, and twice in Hemo-D for 7 min.
Histological scoring. H&E-and trichrome-stained slides were by scored independently by two investigators blinded to treatment group and genotype. A 10 ϫ 10 square grid on the left ocular was superimposed over a portion of each histological section repeatedly so that all lung tissue was covered once and only once. Using a Nikon light microscope with a ϫ20 ocular and ϫ2 objective lens, we scored each square in the grid as 1 if fibrosis occupied at least 50% of the square and 0 otherwise. The percent fibrosis for each section was determined by adding the number of squares scored with a 1, divided by the number of the squares counted. An average of 549 squares were counted for each section scored.
Quantitation of EC-SOD mRNA. Mouse lung total RNA was isolated using an RNeasy MIDI kit (Qiagen) and then quantitated using a SmartSpec 3000 (Bio-Rad). A Cepheid SmartCycler was used with the following protocol: RETROscript kit (Ambion, Austin, Texas) was used to generate RT product using the manufacturer's protocol with a hot start; for mouse (mEC-SOD) PCR, 2 l of RT product was added to 20 l of water, 1 l of EC-SOD forward primer (50 M TTGTTC-TACGGCTTGCTACTGGC), and 1 l of reverse primer (50 M ATTGCATGCATCTCGGCAGC), 1 l of 0.05ϫ SYBR green (Molecular Probes, Eugene, OR), and one Ready-To-Go PCR bead (Amersham Pharmacia Biotech); the resulting mix was brought to 94°C for 300 s and then cycled 50 times from 94°C for 30 s to 66°C for 30 s. For 18S PCR, an identical protocol was used except that primers were from QuantumRNA 18S internal standards (Ambion) and the 50 cycles were 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s. The ratio of EC-SOD mRNA relative to 18S RNA internal standards was determined using Cepheid SmartCycler software (version 1.01). Total lung 18S RNA was determined using 1% of total RNA for agarose gel electrophoresis followed by ethidium bromide staining and then quantitation (Hitachi Genetic Systems). Total lung EC-SOD mRNA was determined by multiplying total 18S RNA by the ratio of EC-SOD mRNA to 18S RNA.
EC-SOD protein quantitation. The remaining mice had their lungs weighed and then ground in liquid nitrogen. Tissue was then resuspended in lysis buffer (25 mM Tris ⅐ Cl, pH 7.5; 500 NaCl; 5 mM EDTA; 0.5% Triton X-100), homogenized in a tissue shearer and then spun at low speed. The supernatant was assayed for protein concentration using a bicinchoninic acid protein assay (Pierce). Identical amounts of protein were boiled for 5 min in SDS sample buffer with 50 mM dithiothreitol and then run into a 12% acrylamide gel. The proteins were transferred to 0.22 M nitrocellulose. A Western blot using either ␤-actin (Sigma) or rabbit polyclonal ␣-EC-SOD antibody was quantitated using ECL ϩPlus and a Molecular Dynamics imaging system (Sunnyvale, CA).
Collagen assay. A complete description of this assay can be found in Lopez-De Leon and Rojkind (22) . In brief, paraffinembedded sections were soaked in Hemo-D to remove the paraffin. Samples were then placed in a (1:1) Hemo-D:ethanol mixture, then 100% ethanol, then 50% ethanol, then distilled water followed by 0.5 ml of sirius red and fast green FCF mixture in 0.1% picric acid. After 30 min, the solution was pulled off, and the samples washed three times in distilled water. Next, 0.25 ml of NaOH 0.1 N and 0.25 ml of methanol were added for one min. Samples were aspirated and absorbance measured at 540 and 605 nm using a 96-well plate reader. The amount of noncollagenous protein in milligram per sample was calculated by measuring the absorbency of the eluate at 605 nm divided by 2.22 (the lung fast green FCF color equivalence). The amount of collagenous protein was calculated by measuring the absorbance of the eluate at 540 nm, subtracting 29% of the absorbance at 605 nm, and then dividing by 36.3 (the sirius red color equivalence). The total amount of collagen per lung was calculated by multiplying the total protein of the lung with the ratio of collagenous protein to total protein.
Statistical analysis. All mice came from the same C57/Bl6 background. Wild-type animals were littermates of EC-SOD transgene-positive animals. A one-way analysis of variance (ANOVA) was used to determine if the means were significantly different (P Ͻ 0.05). If means were significantly different, a Tukey-Kramer multiple group comparison test was used to compare individual groups. Standard error was indicated for each value by a bar, and significance listed for each comparison. A 2 -test was used to calculate P values for ratios. All values were calculated using GraphPad Prism version 3.00 for Macintosh (GraphPad Software, San Diego, CA).
RESULTS
Physiological changes in the lung after bleomycin treatment. Overall mortality was 4/141 (3%). The mortality for the bleomycin-treated mice was 2/56 (3%) for wild types and 2/58 (3%) for the EC-SOD transgenics. For the saline-treated mice, mortality was 0/14 (0%) in the wild types and 0/13 (0%) in the EC-SOD transgenics. Although bleomycin-treated wild-type mice lost 17.7 Ϯ 2.6% of their body weight and the saline-treated wild-type mice gained 8.1 Ϯ 1.4% of their body weight (P Ͻ 0.001 for saline vs. bleomycin treated), overexpression of EC-SOD did not significantly attenuate this weight loss [17.6 Ϯ 3.9% decrease in wild-type vs. 18.3 Ϯ 3.2% decrease in EC-SOD transgenic mice, P ϭ not significant (NS); see Fig. 1 ].
Lung fibrosis is characterized by restrictive physiology. After bleomycin-induced fibrosis, lung volumes decreased by 0.19 Ϯ 0.04 ml in wild-type mice. The EC-SOD transgenic mice had less loss of lung volume (0.10 Ϯ 0.08 ml), although this did not reach statistical significance. Because the most significant physiological abnormality of lung fibrosis is reduced lung volume, our results suggest that there may be a trend toward improved lung physiology in the bleomycin-treated EC-SOD transgenic mice compared with controls.
The lung wet/dry ratio was used to assess lung edema (Fig. 1 ). This ratio was significantly higher after bleomycin treatment in both the wild-type (4.3 Ϯ 0.1 in the saline-treated mice vs. 6.2 Ϯ 0.6 in the bleomycintreated wild-type mice) and EC-SOD transgenic mouse lung (4.5 Ϯ 0.2 in the saline-treated vs. 5.4 Ϯ 0.2 in the bleomycin-treated). EC-SOD transgene expression led to a 52% reduction in the increase in lung edema as measured by the wet/dry ratio. Thus overexpression of EC-SOD in the lungs led to reduced lung edema but was not sufficient to cause a decrease in mortality or airway function.
EC-SOD increases after bleomycin treatment. Because bleomycin accumulates in the lung and EC-SOD is found in abundance in lung, we hypothesized that the oxidative stress from bleomycin would induce EC-SOD. To test this hypothesis, we measured both EC-SOD protein ( Fig. 2A) and mRNA (Fig. 2B) . After bleomycin administration, total lung mouse EC-SOD protein increased slowly over 2 wk. At the end of 2 wk, there was a 106 Ϯ 25% increase in the wild-type mice (P Ͻ 0.05) and 115 Ϯ 25% increase in EC-SOD transgenic mice. The increase in mouse EC-SOD was found even when the data were expressed per milligram protein, actin, or collagen. There was no increase in human EC-SOD in the EC-SOD transgenic mouse lungs. There was also a trend toward increased total lung mouse EC-SOD mRNA in the wild-type (increase of 65 Ϯ 46% compared with control; P ϭ 0,07) and EC-SOD transgenic mice (increase of 140 Ϯ 76% compared with control; P ϭ 0,08). This trend occurred mainly between days 10 and 14.
Prior work by our laboratory has revealed the EC-SOD is secreted in two different forms: one that is proteolytically processed and one that is not (10) . The intracellular processing removes the carboxy terminus and decreases EC-SOD's affinity toward the extracellular matrix. To investigate whether bleomycin would Fig. 1 . Lung edema is attenuated after bleomycin injury in mice overexpressing extracellular superoxide dismutase (EC-SOD) in the lungs. Lung edema, as assessed by the ratio of wet lung weight to dry lung weight, increased 2 wk after bleomycin treatment in both wild-type (**P Ͻ 0.001) and EC-SOD transgenic mice ( †P Ͻ 0.001). The wet/dry lung weight ratio increased to a smaller extent in the EC-SOD transgenic mice compared with wild-type mice (*P Ͻ 0.05). change intracellular proteolytic processing, we used Western blotting to quantitate the ratio of EC-SOD that had been proteolytically processed to the EC-SOD that had not been proteolytically processed. Two weeks after bleomycin, the ratio remained unchanged (0.84 Ϯ 0.02 vs. 0.85 Ϯ 0.01, P ϭ NS), suggesting that the number of cells secreting EC-SOD had increased or that the processing protease increased proportionately to the increase in EC-SOD secretion.
Lung collagen after bleomycin instillation. Bleomycin treatment increased collagen deposition in the wild-type lung (saline-treated 121 Ϯ 33 g vs. bleomycin-treated 277 Ϯ 18 g; P Ͻ 0.001; Fig. 3 ). Overexpression of EC-SOD still resulted in lung collagen accumulation (saline-treated EC-SOD transgenic mice 141 Ϯ 17 g vs. bleomycin-treated EC-SOD transgenic mice 228 Ϯ 18 g, P Ͻ 0.001); however, the lungs from bleomycin-treated EC-SOD transgenic mice had less collagen than the wild-type (P Ͻ 0.05). After bleomycin treatment, the EC-SOD transgenic mice also had a trend toward less total lung weight (EC-SOD transgenic 370 Ϯ 21 mg vs. wild-type 399 Ϯ 30 mg) and less collagen per protein (EC-SOD transgenic 35 Ϯ 3 g collagen/ mg protein vs. wild-type 41 Ϯ 1.5 g collagen/mg protein); however, these differences were not statistically significant. Thus after bleomycin treatment, EC-SOD-overexpressing mice had reduced levels of collagen that could be explained only partially by increases in total lung protein.
Effects of overexpression of EC-SOD on histological injury.
To further elucidate the differences in collagen content between the EC-SOD transgenic and wild-type mouse lung, we performed histological evaluation (Fig.  4) . Histological injury was noted in both the wild-type and EC-SOD transgenic mice treated with bleomycin. There was no injury noted in the control mice. Injury consisted of patchy to confluent fibrosis with a leukocytic cellular infiltration. Severe honeycombing was noted in two specimens (one EC-SOD transgenic and one wild type). We could not discern histological differences between the fibrotic foci of the EC-SOD transgenic and wild-type mouse lungs; however, the injured foci appeared to be smaller in the EC-SOD transgenic lungs compared with the wild-type lungs. To quantitate this difference, we used a grid to quantitate the amount of injury of a histological specimen from each animal.
Two weeks after bleomycin, the percentage of lung with fibrosis was higher in the wild-type mice (21.8 Ϯ 2.3%) compared with the EC-SOD transgenic mice (10.2 Ϯ 1.8%; P Ͻ 0.01; Fig. 5 ). Two investigators achieved similar scores independently (wild type: 21.8 Ϯ 2.5% and 21.9 Ϯ 1.7%; EC-SOD transgene positive 10.5 Ϯ 2.3% and 9.8 Ϯ 1.4%). Thus EC-SOD overexpression attenuated the severity of bleomycininduced lung injury by reducing the size of the fibrotic foci.
Immunohistochemistry of EC-SOD after bleomycininduced lung fibrosis. To investigate the distribution of EC-SOD in the lung after bleomycin treatment, we used immunohistochemical staining with polyclonal antibodies raised against EC-SOD. In our negative controls, we found that neither IgG (Fig. 6A ) nor antibody preadsorbed to EC-SOD (not shown) had significant staining. Using an EC-SOD specific antibody, we Fig. 3 . Overexpression of EC-SOD reduces total lung collagen after bleomycin treatment. Two weeks after intratracheal saline (control) or bleomycin, total lung collagen was quantitated. After bleomycin, lung collagen increased by 138% in the wild-type compared with control (*P Ͻ 0.001), but only 66% in the EC-SOD transgenic mouse lungs compared with control ( †P Ͻ 0.05). There was less of an increase in the transgenic mice compared with wild-type mice (¥P Ͻ 0.05). Fig. 4 . Collagen-rich areas of fibrosis are smaller in EC-SOD transgenic mice treated with bleomycin. Two weeks after bleomycin or saline, mice lungs were perfused, fixed, and embedded in paraffin. Sections were stained for collagen with sirius red (red) and for noncollagenous protein with fast green FCF (green) and then photographed at ϫ10 magnification. Both control (A) and bleomycin-treated (B) animals stained for collagen around large airways and blood vessels; however, both wild-type (B) and EC-SOD transgenic-positive (C) animals had foci of fibrosis that stained strongly for collagen (arrows in B and C).
found EC-SOD along alveolar membranes, along large airways, and surrounding blood vessels (Fig. 6B ). In the EC-SOD transgenic mice, there was abundant staining associated with type II alveolar cells (Fig. 6E ) and bronchial epithelial cells (not shown). In most tissue sections there was an occasional alveolar macrophage that stained positive (Fig. 6E) . This staining was consistent with that previously reported by Folz et al. (12) and consistent with the activity of the SPC promoter (6). After bleomycin treatment, both the wildtype and EC-SOD transgenic mice developed patchy fibrosis (Fig. 6, D and F) . Within these areas of fibrosis, staining for EC-SOD appeared more intense and occurred in foci that also stained positively for collagen with sirius red. Although the fibrotic foci appeared smaller in the EC-SOD transgenic mice, the staining within these foci was more intense.
DISCUSSION
Bleomycin is a commonly used chemotherapeutic agent that has severe pulmonary side effects. Although bleomycin is a well-known cause of intracellular oxidative stress, several findings in this study suggest that extracellular oxidative stress may also play a role in the pathogenesis of bleomycin-induced lung injury. First, pulmonary overexpression of EC-SOD attenuated both collagen accumulation and histological injury in the lung after bleomycin administration. Second, bleomycin induced pulmonary EC-SOD protein synthesis and accumulation in the lung.
Other investigators have reported that total lung SOD activity increases in rats (11, 19) and rabbits (27) after bleomycin administration, but this is the first study to specifically report changes in EC-SOD. An interesting feature of the rise in lung EC-SOD is that the protein increased 1 wk before the mRNA. Several possible explanations could account for this. First, EC-SOD half-life might increase in the first few days after bleomycin. Second, the efficiency of EC-SOD mRNA translation might be increased. Third, EC-SOD may come from nonpulmonary sources. Although the source of the increase in lung EC-SOD protein is not known, there was prominent EC-SOD immunostaining in lung macrophages and neutrophils, suggesting that the increase may result from the influx of inflammatory cells. Loenders et al. (21) have also reported immunostaining for EC-SOD in inflammatory cells. Later increases in lung EC-SOD may be sustained by increased lung synthesis, as suggested by the late rise in EC-SOD mRNA.
The mediators that induce EC-SOD gene transcription after bleomycin are unknown. Although the mouse EC-SOD promoter has not been described, the human EC-SOD promoter contains two putative antioxidant response elements (13) . The complete molecular mechanism of signal transduction by ROS is unknown but is currently under study in our laboratory. Although bleomycin induces a burst of ROS, this occurs immediately after administration. Thus the late increase in EC-SOD gene transcription is probably secondary to other mediators. The cytokines that are induced by bleomycin may be better candidates for regulators of EC-SOD gene transcription (32, 36) . Several investigators have found that inflammatory cytokines such as interferon-␥ (2) and interleukin-1 (25) can induce EC-SOD in rat and human cell culture lines. One pathway common to both of these pathways is nuclear factor-B (2). Nuclear factor-B is also a putative regulatory element in the human EC-SOD gene (13) . Thus early increases in EC-SOD may be a result of an influx of inflammatory cells that carry EC-SOD protein, yet, later increases may be secondary to the effects of the cytokine milieu on EC-SOD gene transcription. However, in this model, bleomycin was administered as a single dose; thus the level of lung EC-SOD before bleomycin administration may be more important than any subsequent induction of native mouse EC-SOD protein.
The difference in expression between the endogenous EC-SOD and the transgene EC-SOD is not surprising since the genes are under control of different promoters. The EC-SOD transgene utilized the human SPC promoter and not the mouse EC-SOD promoter. Our findings that bleomycin does not increase the EC-SOD transgenic protein are consistent with previous studies, which report that the SPC promoter is activated only in a sporadic manner after bleomycin injury (6, 7) . Additionally, the cytokines that increase EC-SOD in cell culture have not been found to increase SPC message in whole lung preparations (5, 34) .
There are several mechanisms by which EC-SOD may protect the lung from injury. Bleomycin administration generates free radicals that injure DNA (26, 40) , lipids (15) , and proteins (44) . Superoxide is one of these free radical mediators and the lung is a major target organ of bleomycin injury. EC-SOD is abundant in lung tissue (24) and could directly attenuate lung injury by reducing superoxide concentrations in the extracellular space. Reduction of superoxide in the extracellular space might have several consequences, including decreased stimulation of fibroblasts and diminished inflammatory cell recruitment. For instance, Fig. 5 . Overexpression of EC-SOD reduces lung injury after bleomycin administration. We scored mouse lungs for fibrosis by overlaying a grid onto lung sections stained with hematoxylin and eosin and Masson's trichrome. Each square on the grid was counted as positive if fibrosis occurred in Ͼ50% of the square and negative if there was Ͻ50% fibrosis. Two weeks after bleomycin administration, the percentage of lung that was fibrotic was significantly less in the EC-SOD transgenic mice compared with wild type (*P Ͻ 0.01).
bleomycin-induced superoxide production has been shown to stimulate fibroblasts to proliferate and differentiate into myofibroblasts, resulting in a histological appearance that is similar to idiopathic pulmonary fibrosis (41) . Superoxide stimulates fibroblasts to secrete collagen (3) and mediates expression of selectins on endothelium, resulting in enhanced recruitment of leukocytes to the lung (1). Thus EC-SOD may protect both directly as an antioxidant and indirectly by blunting the initial inflammation that is induced during bleomycin administration.
The attenuation of bleomycin-induced lung injury with EC-SOD transgene overexpression was similar to that reported by Tamagawa et al. (38) with intravenous lecithinized SOD1. With a dose of either 1 or 10 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 , these investigators found an 11% reduction in lung weight, 16% reduction in lung collagen, and 41% reduction in grade of fibrosis. Other investigators have found similar reductions in lung edema, collagen deposition, and fibrosis score after administration of high levels of SOD2 (31) and other ROS scavengers (30) . Although these investigators did not report how much the injections increased lung SOD activity, it is likely that their beneficial effect was secondary to enhanced intravascular SOD activity, since all of these treatments were given parenterally. In the EC-SOD transgenic mice, EC-SOD overexpression occurred primarily in alveolar type II cells and bronchial epithelial cells (12) , suggesting that both the airway and alveolar epithelium may be important in defending against free radical injury after bleomycin. Furthermore, it is unlikely that the reduced lung injury in the EC-SOD transgenic mice is due to differences other than an increase in EC-SOD, since cytosolic SOD, mitochondrial SOD, glutathione peroxidase, glutathione, and catalase have been reported to be identical in the lungs of wild-type and EC-SOD transgenic mice (12) . Although the protection afforded by EC-SOD overexpression was modest and incomplete, this is the first report to suggest that alveolar and airway extracellular antioxidant enzymes can protect the lung from bleomycin-induced lung fibrosis. This study was not statistically powered to detect differences in secondary outcomes such as weight loss and mortality. The lack of statistically significant improvement in these multifactorial outcomes confirms that mediators besides extracellular superoxide play a large role in the pathogenesis of bleomycin-induced lung injury.
There are several compelling reasons why extracellular antioxidants might be beneficial in clinical treatment or prevention of pulmonary fibrosis. First, patients with pulmonary fibrosis have reduced epithelial lining fluid antioxidant capacity and elevated markers of oxidative stress (35) . Second, administration of aerosolized glutathione has been shown to attenuate bleomycin-induced lung fibrosis (16, 23) . Third, alveolar inflammatory cells from patients with pulmonary fi- Fig. 6 . Immunohistochemistry of bleomycin-treated animals shows intense staining for EC-SOD in fibrotic areas in the mouse lung. A: wild-type mouse lung (high power) using IgG control shows no brown pigment. B: wild-type mouse lung (medium power) using polyclonal EC-SOD antibody that stains brown. There is staining around large airways, blood vessels, and in the alveolar interstitium. C: wild-type mouse lung (high power) reveals EC-SOD immunoreactivity in the alveolar interstitium. D: wild-type mouse lung 2 wk after bleomycin (high power) shows intense staining for EC-SOD in foci of injured lung; these areas appear to be extracellular (thick arrows) and stained for collagen with sirius red (high power). E: EC-SOD transgenic mouse lung (high power) shows strong EC-SOD staining associated with type II alveolar cells (thin arrows) F: 2 wk after bleomycin, EC-SOD transgenic mouse lung (high power) have smaller foci of injured lung. EC-SOD staining appears to be extracellular (large arrows) and associated with foci that stained positive with sirius red. An alveolar macrophage shows slight intracellular staining. Bars represent 10 m.
brosis produce excess extracellular superoxide (37) . Thus targeting the extracellular space with mimics of EC-SOD may be a potentially beneficial intervention in patients suffering from pulmonary fibrosis or undergoing bleomycin chemotherapy.
In conclusion, bleomycin administration induced EC-SOD in the lung and overexpression of EC-SOD attenuated bleomycin-induced fibrosis. The only difference in the lungs that could explain the decreased fibrosis was a higher level of EC-SOD in the EC-SOD transgenic lungs [0.5 g EC-SOD/mg lung protein in the wild-type vs. 1.5 g EC-SOD/mg lung protein in the EC-SOD transgenic mice (12) ]. Thus microgram amounts of extracellular SOD activity appear to be biologically effective at reducing bleomycin-induced lung fibrosis. This suggests that small increases in pulmonary extracellular SOD activity, by either pretreatment with EC-SOD or an extracellular SOD mimic, may be of potential therapeutic benefit in reducing bleomycin-induced lung injury.
